Immunoassay Market: Global Market Estimation, Dynamics, Trends, Competitor Analysis 2015-2020 and Forecast 2021-2027

$ PRICE - $ 3,000.00$ 8,900.00

Immunoassay Market By Type (Radioimmunoassay (RIA), Enzyme Immunoassays (EIA), Fluoroimmnoassay (FIA) Chemiluminescence immunoassay (CLIA) and Others), By Application (Disease Diagnosis, Therapeutic Drug Monitoring, Drug Discovery, Clinical Chemistry, Hematology, and Others), By End User (Hospitals, Pharma & Biotech Companies, Clinical Laboratories and Others), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Immunoassay market size is expected to be worth USD 27,049.8 million in 2022, growing at a high CAGR of 5.1% from 2022 to 2028 to reach USD 36,456.9 million in 2028. The increasing prevalence of acute and chronic infectious diseases, the rising geriatric population, growing awareness for early disease diagnosis, technological advancements in immunoassays, increasing use of immunoassays in precision oncology and drug & alcohol testing, and the emergence of COVID-19 are driving the immunoassay market. Antibodies bind to antigens in immunoassay tests, which allows users to detect and analyze specific chemicals. Immunoassays are a type of test that can be used to diagnose disease. Additionally, test findings can reveal information about an illness that can aid in therapy planning (for example, when estrogenic receptors are measured in breast cancer). Enzyme Immunoassay had a market revenue share of 37.3% in 2021, and it is expected to grow at a CAGR of 4.9% from 2022 to 2028. It has a number of advantages; the main advantage of enzyme immunoassay over immunodiffusion or immunoelectrophoresis procedures is reduced assay time. Disease diagnosis is expected to have an xx percent market revenue share from 2022 to 2028. However, the Immunoassay market is hampered by Stringent Regulatory Requirements for the Approval of Immunoassay Instruments and Consumables.

Key Developments:

In October 2020, Thermo Fisher Scientific launched its EliA SARS-CoV-2-Sp1 IgG test and OmniPATH COVID-19 Total Antibody ELISA test, for the diagnosis of COVID-19 antibodies

In January 2021, Abbott received the CE Mark for its Panbio COVID-19 Ag Rapid Test Device for the asymptomatic diagnosis of the SARS-CoV-2 virus. It also offers self-swabbing

In December 2020, Beckman Coulter, part of Danaher (US) company, launched the first high-quality and throughput assay, called Access SARS-CoV-2 Antigen assay, for the COVID-19 antigen diagnosis, in the US

Immunoassay Market

MARKET SUMMARY
-
5.1%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 5.1%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Immunoassays Market

  • The immunoassay market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The immunoassay market is segmented based on based on product type, application, end-user, and geography.
Key Players
  • Bio-Rad Laboratories Inc.
  • Thermo Fisher Scientific
  • EMD Millipore (Merck KGaA.
  • Becton, Dickinson and Company.
  • Quansys Biosciences Inc
Immunoassay Market Growth

The immunoassay market is surging owing to frequent acquisitions and launchings by the market players. Strategic alliances by the players, such as acquisitions, mergers, expansions, and new product launches, may enhance the company’s growth.


North-America Got Significant Share

Immunoassays Market

North America is predicted to have the largest share of the Immunoassay market by 2028, and it is expected to grow rapidly in the following years. The North American market's substantial share is due to its well-established market, fueled by rising per capita healthcare spending and the availability of technologically advanced healthcare infrastructure in the area.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The immunoassay market report provides granular level information about the market size, regional market share, historic market (2015 to 2020) and forecast (2021 to 2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Immunoassay Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The immunoassay market is projected to expand at a CAGR of 5.1% during the forecast period.

Bio-Rad Laboratories Inc., Thermo Fisher Scientific , EMD Millipore (Merck KGaA., Becton, Dickinson and Company., Microsynth AG, Quansys Biosciences Inc , QIAGEN N.V., Hoffmann-La Roche Ltd.

North America is dominating the immunoassay market


Report

Table Of Content


Report

Company Profile

  • Bio-Rad Laboratories Inc.
  • Thermo Fisher Scientific
  • EMD Millipore (Merck KGaA.
  • Becton, Dickinson and Company.
  • Microsynth AG
  • Quansys Biosciences Inc
  • QIAGEN N.V.
  • Hoffmann-La Roche Ltd.
  • Danaher Corporation.
  • Luminex Corporation

Description

Immunoassay market size is expected to be worth USD 27,049.8 million in 2022, growing at a high CAGR of 5.1% from 2022 to 2028 to reach USD 36,456.9 million in 2028. The increasing prevalence of acute and chronic infectious diseases, the rising geriatric population, growing awareness for early disease diagnosis, technological advancements in immunoassays, increasing use of immunoassays in precision oncology and drug & alcohol testing, and the emergence of COVID-19 are driving the immunoassay market. Antibodies bind to antigens in immunoassay tests, which allows users to detect and analyze specific chemicals. Immunoassays are a type of test that can be used to diagnose disease. Additionally, test findings can reveal information about an illness that can aid in therapy planning (for example, when estrogenic receptors are measured in breast cancer). Enzyme Immunoassay had a market revenue share of 37.3% in 2021, and it is expected to grow at a CAGR of 4.9% from 2022 to 2028. It has a number of advantages; the main advantage of enzyme immunoassay over immunodiffusion or immunoelectrophoresis procedures is reduced assay time. Disease diagnosis is expected to have an xx percent market revenue share from 2022 to 2028. However, the Immunoassay market is hampered by Stringent Regulatory Requirements for the Approval of Immunoassay Instruments and Consumables.

Key Developments:

In October 2020, Thermo Fisher Scientific launched its EliA SARS-CoV-2-Sp1 IgG test and OmniPATH COVID-19 Total Antibody ELISA test, for the diagnosis of COVID-19 antibodies

In January 2021, Abbott received the CE Mark for its Panbio COVID-19 Ag Rapid Test Device for the asymptomatic diagnosis of the SARS-CoV-2 virus. It also offers self-swabbing

In December 2020, Beckman Coulter, part of Danaher (US) company, launched the first high-quality and throughput assay, called Access SARS-CoV-2 Antigen assay, for the COVID-19 antigen diagnosis, in the US

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX